United Therapeutics Corp
UTHR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001082554
In the last 90 days, United Therapeutics Corp insiders filed 0 open-market purchases and 71 sales; 886 institutions reported holding it in 13F filings for Q2 2026, worth $22.7B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $337.0M in total
- 71
- 13F holdersQ2 2026, +40 vs. previous quarter
- 886
- 13F valueReported value at the end of Q2 2026
- $22.7B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding UTHR, Q2 2026
No superinvestor reported holding UTHR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by United Therapeutics Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 (view filing)4:31 PM ET | Sep 24 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $473.55 | −$4.50M | −2.8%324.4K after | 11 lots10b5-1 |
| Sep 24, 2026 (view filing)4:31 PM ET | Sep 23 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $491.57 | −$4.67M | −2.8%324.4K after | 12 lots10b5-1 |
| Sep 23, 2026 (view filing)4:30 PM ET | Sep 22 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $494.83 | −$4.70M | −2.8%324.4K after | 10 lots10b5-1 |
| Sep 22, 2026 (view filing)4:33 PM ET | Sep 21 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $494.55 | −$4.70M | −2.8%324.4K after | 5 lots10b5-1 |
| Sep 21, 2026 (view filing)4:44 PM ET | Sep 18 | 3 days | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $494.79 | −$4.70M | −2.8%324.4K after | 6 lots10b5-1 |
| Sep 18, 2026 (view filing)4:41 PM ET | Sep 17 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $496.06 | −$4.71M | −2.8%324.4K after | 9 lots10b5-1 |
| Sep 18, 2026 (view filing)4:40 PM ET | Sep 17 | 1 day | Mahon Paul AEVP & GENERAL COUNSEL | SSale | −8.30K | $497.54 | −$4.13M | −15.5%45.2K after | 7 lots10b5-1 |
| Sep 17, 2026 (view filing)4:43 PM ET | Sep 16 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $501.39 | −$4.76M | −2.8%324.4K after | 8 lots10b5-1 |
| Sep 16, 2026 (view filing)4:35 PM ET | Sep 15 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $501.59 | −$4.77M | −2.8%324.4K after | 6 lots10b5-1 |
| Sep 15, 2026 (view filing)4:34 PM ET | Sep 14 | 1 day | Rothblatt Martine AChairperson & CEO | SSale | −9.50K | $504.12 | −$4.79M | −2.8%324.4K after | 5 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in United Therapeutics Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,294,529 | $2.87B | 0.04% | −105,120−1.9% | Reduced |
| Avoro Capital Advisors LLC | 2,777,777 | $1.51B | 13.52% | +147,777+5.6% | Added |
| Vanguard Portfolio Management LLC | 1,919,429 | $1.04B | 0.05% | −84,313−4.2% | Reduced |
| Vanguard Capital Management LLC | 1,918,256 | $1.04B | 0.02% | −39,283−2.0% | Reduced |
| State Street Corp | 1,898,064 | $1.03B | 0.03% | +54,101+2.9% | Added |
| Renaissance Technologies LLC | 1,708,739 | $925.8M | 1.27% | −78,280−4.4% | Reduced |
| Wellington Management Group LLP | 1,379,025 | $747.2M | 0.13% | −885,222−39.1% | Reduced |
| Geode Capital Management, LLC | 996,598 | $538.9M | 0.03% | −236,431−19.2% | Reduced |
| Jupiter Topco LLC | 831,129 | $450.1M | 0.18% | +831,129 | New |
| Norges Bank | 694,753 | $376.4M | 0.04% | +694,753 | New |